GETI.B

211.5

-0.28%↓

BIOAB

317.4

-0.69%↓

EKTA.B

56.6

+0.62%↑

VITR

137.3

+3.39%↑

AMBEA

140.7

-0.57%↓

GETI.B

211.5

-0.28%↓

BIOAB

317.4

-0.69%↓

EKTA.B

56.6

+0.62%↑

VITR

137.3

+3.39%↑

AMBEA

140.7

-0.57%↓

GETI.B

211.5

-0.28%↓

BIOAB

317.4

-0.69%↓

EKTA.B

56.6

+0.62%↑

VITR

137.3

+3.39%↑

AMBEA

140.7

-0.57%↓

GETI.B

211.5

-0.28%↓

BIOAB

317.4

-0.69%↓

EKTA.B

56.6

+0.62%↑

VITR

137.3

+3.39%↑

AMBEA

140.7

-0.57%↓

GETI.B

211.5

-0.28%↓

BIOAB

317.4

-0.69%↓

EKTA.B

56.6

+0.62%↑

VITR

137.3

+3.39%↑

AMBEA

140.7

-0.57%↓

Home・Akcijų sąrašas・Camurus AB

Camurus AB

Atidarymo kaina

600.5 -1.31

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

594

Max

608.5

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-99M 193M
Pardavimai	-108M 567M
P/E Sektoriaus vid.	46.937 76.798
Pelnas, tenkantis vienai akcijai	3.19
Pelno marža	33.972
Darbuotojai	280
EBITDA	-62M 253M

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	432M 37B
Ankstesnė atidarymo kaina	601.81
Ankstesnė uždarymo kaina	600.5

Camurus AB Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-19 17:29; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

2025-12-19 16:47; UTC

Pagrindinės rinkos jėgos

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

2025-12-19 16:10; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

2025-12-21 23:51; UTC

Rinkos pokalbiai

Oil Rises Amid Growing U.S.-Venezuela Tensions -- Market Talk

2025-12-21 23:45; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-21 23:45; UTC

Rinkos pokalbiai

Nikkei May Rise as Yen Weakens -- Market Talk

2025-12-21 23:35; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Geopolitical Tensions -- Market Talk

2025-12-19 22:33; UTC

Uždarbis

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

2025-12-19 22:19; UTC

Uždarbis

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

2025-12-19 21:48; UTC

Įsigijimai, susijungimai, perėmimai

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025-12-19 21:44; UTC

Uždarbis

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

2025-12-19 21:38; UTC

Uždarbis

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

2025-12-19 21:00; UTC

Rinkos pokalbiai

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

2025-12-19 20:23; UTC

Rinkos pokalbiai

Oil Futures End Down Week on Up Note -- Market Talk

2025-12-19 20:14; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

2025-12-19 18:38; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

2025-12-19 18:00; UTC

Rinkos pokalbiai

Uždarbis

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

2025-12-19 17:41; UTC

Uždarbis

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

2025-12-19 17:24; UTC

Rinkos pokalbiai

Uždarbis

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

2025-12-19 17:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-12-19 17:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-12-19 16:29; UTC

Uždarbis

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

2025-12-19 16:20; UTC

Įsigijimai, susijungimai, perėmimai

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

2025-12-19 16:19; UTC

Įsigijimai, susijungimai, perėmimai

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

2025-12-19 16:18; UTC

Įsigijimai, susijungimai, perėmimai

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

2025-12-19 16:16; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-19 16:16; UTC

Rinkos pokalbiai

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

2025-12-19 16:05; UTC

Įsigijimai, susijungimai, perėmimai

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025-12-19 16:04; UTC

Įsigijimai, susijungimai, perėmimai

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025-12-19 15:37; UTC

Rinkos pokalbiai

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

Akcijų palyginimas

Kainos pokytis

Camurus AB Prognozė

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.